Summary of “Ventilator-Induced Lung Injury: The Unseen Challenge in Acute Respiratory Distress Syndrome Management” (Merola et al.)
Abstract Summary: Merola et al. comprehensively review ventilator-induced lung injury (VILI) within acute respiratory distress syndrome (ARDS) management, underscoring the complex interplay of pathophysiological mechanisms. The authors discuss traditional and emerging concepts such as volutrauma, barotrauma, atelectrauma, biotrauma, ergotrauma, and heterogeneous lung mechanics, highlighting current lung-protective strategies and novel personalized ventilation approaches aimed at reducing VILI and improving patient outcomes.
Key Points:
-
Introduction to VILI: Mechanical ventilation (MV) is essential in ARDS but can cause significant harm (VILI), historically known but clearly demonstrated clinically only after recognizing reduced mortality with lung-protective strategies.
-
Mechanisms of VILI (Barotrauma and Volutrauma): VILI occurs via multiple mechanisms, including barotrauma (high pressure), volutrauma (overdistension), and excessive transpulmonary pressure, which are closely interrelated rather than distinct entities.
-
Atelectrauma: The cyclic opening and collapse of alveoli (atelectrauma), exacerbated by surfactant dysfunction and dependent edema, significantly contributes to lung damage. Strategies that minimize repetitive alveolar collapse (e.g., higher PEEP) are protective but require careful titration.
-
Biotrauma: Mechanical ventilation can trigger inflammatory cascades (“biotrauma”), causing systemic inflammation and multiorgan failure. Clinical trials demonstrate lung-protective strategies significantly reduce systemic inflammation and multiorgan dysfunction.
-
Ergotrauma and Mechanical Power (MP): Mechanical power, incorporating tidal volume (VT), respiratory rate (RR), and inspiratory pressures, provides a comprehensive marker for ventilatory-induced stress. Excessive MP (>17 J/min) is linked to higher mortality rates, suggesting potential use in personalizing ventilation settings.
-
Personalized Ventilation: Lung-protective ventilation with low VT (4–6 mL/kg predicted body weight [PBW]) and tailored positive end-expiratory pressure (PEEP) is standard but may not suit all patients. Emerging approaches involve esophageal pressure measurements, electrical impedance tomography (EIT), and individualized ventilatory strategies.
-
Prone Positioning: Prone positioning redistributes lung aeration, reduces regional lung strain, improves oxygenation, and significantly reduces mortality in severe ARDS, particularly with prolonged sessions (>12–16 hours/day).
-
Ultra-Protective Ventilation and Extracorporeal Support: Ultra-protective ventilation strategies (VT <4 mL/kg PBW) facilitated by extracorporeal life support (ECLS), including extracorporeal carbon dioxide removal (ECCO₂R) and ECMO, show potential benefits but require careful management to avoid complications.
-
Biological Subphenotypes and Pharmacological Interventions: Distinct ARDS biological subphenotypes (hyperinflammatory vs. hypoinflammatory) respond differently to interventions. Emerging therapies like mesenchymal stem cells and targeted anti-inflammatory agents, though promising, require further validation.
-
Future Directions and Precision Medicine: Future ARDS management should integrate advanced monitoring (MP, transpulmonary pressure), biological phenotyping, and artificial intelligence tools. Personalized ventilation strategies, guided by patient-specific lung mechanics and real-time monitoring, hold promise for further reducing VILI and improving survival.
Conclusion: Despite advances in understanding and managing VILI, significant challenges persist in identifying universally optimal ventilation strategies. A shift from standardized ventilation protocols to personalized, physiology-based, and phenotype-driven approaches, leveraging advanced monitoring technologies and precision medicine frameworks, is essential to further mitigate lung injury and enhance patient outcomes.
Watch the following video on “IM Grand Rounds: Advancements in ARDS: Latest Definition and Management Strategies in 2024” by NGHS Continuing Medical Education
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

